<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815748</url>
  </required_header>
  <id_info>
    <org_study_id>HR-SP2086-109</org_study_id>
    <nct_id>NCT02815748</nct_id>
  </id_info>
  <brief_title>The Metabolite Identification and Material Balance Study of SP2086</brief_title>
  <official_title>A Single-center, Randomized, Open, Single Dose Phase I Study to Access the Metabolite Identification and Material Balance in Health Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the Metabolite identification and material balance
      of SP2086 in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects were given SP2086 100mg only one time, and blood sample should be collected
      before and 96 hours after medicine taken.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of SP2086</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of SP2086 acid</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of SP2086</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of SP2086 acid</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>SP2086</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SP2086 was taken only one time at 100mg dose in health volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP2086</intervention_name>
    <description>SP2086 was taken only one time at 100mg dose in health volunteers</description>
    <arm_group_label>SP2086</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers with a body mass index(BMI) between 19 and 25 Kg/m2,and weight
             â‰¥50kg.

          -  Lab and other examination results were normal or mildly abnormal without clinical
             significance, clinical doctors had considered eligible.

          -  Had signed the informed consent himself or herself voluntarily.

        Exclusion Criteria:

          -  Has a history of severe system disease, or family history (including the
             cardiovascular system, digestive system, urinary system, etc.).

          -  Has a history of allergy or intolerance to SP2086 OR other DPP-IV.

          -  The subjects participated 3 times or more than 3 times drug clinical subjects in
             nearly a year;participate any drug clinical trial prior to the test 3 months, or had
             blood donor, or plan to blood donors three months before the test;or had a transfusion
             in 4 weeks.

          -  Did not take effective contraceptive measures or planning of the subjects in half a
             year.

          -  Researchers considered the patient adherence is poor, or has any unfavorable factors
             that not suit to participate the test.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XingHe Wang, P.H.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Shijitan Hospital,affiliated to Capital Medical University</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SP2086</keyword>
  <keyword>Metabolite identification</keyword>
  <keyword>Material balance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

